Lonza Sells Capsule Unit to Lone Star for $3 Billion
Lonza will sell its capsule unit to Lone Star for $3 billion to focus on drug manufacturing. The Swiss firm will retain a 40% stake in the divested business.
Xurve View
Insights:
Xurve View
Lonza Group AG has reached a definitive agreement to sell its capsules and health ingredients business to the private equity firm Lone Star Funds for an enterprise value of 2.3 billion Swiss francs, or approximately $3.0 billion. The divestiture marks a major strategic shift for the manufacturer, which is based in Switzerland, as it moves toward a singular focus on its core contract drug manufacturing services.
